Acrux Limited (ARUXF) Research

Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels. Additionally, Acrux provides estradiol sprays, sold under the brand names Evamist and Lenzetto, specifically formulated for women experiencing hot flashes associated with menopause. The company, established in 1998, is headquartered in West Melbourne, Australia.

Open Acrux Limited (ARUXF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.